KIT and acute myeloid leukemia: In this study, cabozantinib displayed cytotoxic efficacy in two human AML cell lines, Kasumi-1 and SKNO-1, carrying the t(8;21) and KIT N822K mutation, but the susceptibility of the two cell lines to cabozantinib differed, with IC50 values of 88.06 and 503.55 nM, respectively.